Background We have previously reported that ischemic preconditioning increases 5'-nucleotidase activity and adenosine release during ischemia and reperfusion. However, its direct cause-and-effect relation has not been proven. To test the idea that the infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of ectosolic 5'-nucleotidase activity, we assessed 5'-nucleotidase activity, adenosine release, and infarct size caused by sustained ischemia with and
Background We have previously reported that ischemic preconditioning increases 5'-nucleotidase activity and adenosine release during ischemia and reperfusion. However, its direct cause-and-effect relation has not been proven. To test the idea that the infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of ectosolic 5'-nucleotidase activity, we assessed 5'-nucleotidase activity, adenosine release, and infarct size caused by sustained ischemia with and without an exposure to a,,3,-methylene adenosine 5-diphosphate (AOPCP) in the ischemia-preconditioned myocardium.
Methods and Results
In 67 open-chest dogs, the left anterior descending coronary artery was cannulated and perfused with an extracorporeal bypass tube from the carotid artery. After hemodynamic stabilization, the coronary artery was occluded four times for 5 minutes separated by 5 minutes of reperfusion (ischemic preconditioning, n=10). After this procedure, the coronary artery was occluded for 90 minutes followed by 6 hours of reperfusion. Infarct size normalized by the risk area was smaller than the control group (n=8, 41.0+2.6% versus 6 .8±1.9%), although there were no significant differences in the endomyocardial collateral flow measured at 80 minutes of ischemia (8. 5±1.1 versus 9.4±1.0 mL/100 g per minute). Ectosolic and cytosolic 5'-nucleotidase activity and adenosine release were increased during reperfusion in the ischemic preconditioning group compared with the control group, and the activity of ectosolic 5'-nucleotidase was markedly reduced by AOPCP (n=10). AOPCP affected neither adenosine-induced coronary vasodilation nor increases in myocardial oxygen consumption during an intracoronary infusion of isoproterenol (n= 10). To test whether the increase in 5-nucleotidase activity decreases infarct size, we infused AOPCP 10 minutes before the ischemic preconditioning procedure and continued for 60 minutes after the onset of reperfusion (n=8). AOPCP blunted the infarct size-limiting effect (infarct size, 38 .8+4.9%). AOPCP without ischemic preconditioning did not increase infarct size (n=9). Furthermore, when AOPCP was infused during the ischemic preconditioning procedure (n = 6) or during 60 minutes of reperfusion (n=6), the infarct size-limiting effect was partially blunted (infarct size, 21.3+2.5% and 19.5+2.4%, respectively).
Conclusions Increases in ectosolic 5'-nucleotidase activity and adenosine release are primarily responsible for the infarct size-limiting effect of ischemic preconditioning. Exposures to adenosine during the ischemic preconditioning procedure and enhanced release of adenosine during reperfusion synergistically contribute to the infarct size-limiting effects. (Circulation. 1994; 89:1237 -1246 Key Words * myocardium * ischemia * reperfusion a purine * 5 To test this cause-and-effect relation, we measured adenosine release and infarct size with and without administration of an inhibitor of 5'-nucleotidase, a43,-methylene adenosine 5'-diphosphate (AOPCP). Furthermore, we infused AOPCP during the ischemic preconditioning procedure or during the reperfusion period to discriminate the roles of increased 5'-nucleotidase activity and adenosine release during these two periods.
Methods Instrumentation
Sixty-seven mongrel dogs weighing 12 to 21 kg were anesthetized with sodium pentobarbital (30 mg/kg IV), intubated, and ventilated with room air mixed with oxygen (100% 02 at 1 to 2 L/min). The chest was opened through the left fifth intercostal space, and the heart was suspended in a pericardial cradle. After intravenous administration of heparin (500 units/ kg), we cannulated and perfused the left anterior descending (LAD) coronary artery with blood from the left carotid artery through an extracorporeal bypass tube. Coronary blood flow (CBF) in the perfused area was measured using an electromagnetic flow probe attached to the bypass tube, and coronary perfusion pressure (CPP) was monitored at the tip of the coronary artery cannula. A small-caliber (1 mm), short (7 cm) collecting tube was cannulated into a small coronary vein near the center of the perfused area to sample coronary venous blood. Drained venous blood was collected in a reservoir placed at the level of the left atrium and was returned to the jugular vein. Heart rate averaged 137±3 beats per minute during control conditions and did not change during the study with and without an intracoronary infusion of AOPCP. The pH, Po2, and Pco2 in the systemic arterial blood before the protocol were 7.41+0.02, 121±5, and 39.6±2.5 mm Hg, respectively.
Experimental Protocols
Protocol 1: Effects of AOPCP on the Infarct
Size-Limiting Effect of Ischemic Preconditioning
Forty-seven dogs were used in this protocol. CPP and CBF were measured continuously. Coronary arterial and venous blood were sampled for blood gas analysis and measurement of plasma adenosine concentration. After hemodynamic stabilization, four cycles of coronary occlusion and subsequent reperfusion for 5 minutes each were performed to precondition the myocardium to sustained ischemia (n=10, ischemic preconditioning [IP] group). In this ischemic preconditioning group, coronary venous blood was sampled before and immediately after each 5 minutes of coronary occlusion. Arterial blood was also sampled at 60-to 90-minute intervals to check the condition of the dogs. After 90 minutes of coronary occlusion, coronary venous blood was sampled after 1, 5, 10, 30, 60, and 120 minutes of reperfusion. As a control, instead of the ischemic preconditioning procedure, after 40 minutes of hemodynamic stabilization, the coronary artery was occluded for 90 minutes and reperfused for 360 minutes (n=8, control group). Coronary arterial and venous blood was sampled at 20-minute intervals during 40 minutes of hemodynamic stabilization and was sampled after 1, 5, 10, 30, 60, and 120 minutes of reperfusion after 90 minutes of ischemia.
In 8 other dogs, 80 ,pg* kg-l1 mnin-AOPCP (Sigma Chemical Co) was administered into the LAD coronary artery S minutes before the ischemic preconditioning procedures and was continued for 60 minutes of reperfusion except for the coronary occlusion period (the AOPCP treatment with IP group). In 9 dogs, AOPCP was administered into the LAD coronary artery 40 minutes before ischemia and was continued for 60 minutes of reperfusion except for the coronary occlusion period (the AOPCP treatment group). AOPCP was dissolved with saline and infused into the perfusion line at the rate of 0.33 mL/min.
To discriminate the role of increases in 5'-nucleotidase activity during the ischemic preconditioning procedure (the AOPCP pretreatment with IP group, n=6) or during reperfusion (the AOPCP during reperfusion with IP group, n=6) on the infarct size-limiting effect, we infused AOPCP (80 ug * kg-min-IC) only during the ischemic preconditioning procedure or only during reperfusion up to 60 minutes in the ischemia-preconditioned dogs.
Arterial and coronary venous blood samplings in these groups were performed at the same timing as in the control and IP groups, respectively.
Protocol 2: Effects of Ischemic Preconditioning on
Ectosolic and Cytosolic 5'-Nucleotidase Activity in the Myocardium Ten dogs were used in protocol 2. Using two groups of 5 dogs each with and without ischemic preconditioning, we measured 5'-nucleotidase activity in the endocardial and epicardial myocardium before sustained ischemia after separation of the myocardium into membrane and cytosolic fractions. 
Measurements of Infarct Size
After 6 hours of reperfusion in protocol 1, while the LAD was reoccluded and perfused with autologous blood, Evans blue dye was injected into the systemic vein to determine the anatomic risk area and the nonischemic area in the hearts. The heart was removed immediately and sliced into serial transverse sections 6 to 7 mm in width. The nonischemic area was separated as the blue-staining normal area, and the ischemic region was incubated at 37°C for 20 to 30 minutes in 1% 2,3,5-triphenyltetrazolium chloride (TTC, Sigma Chemical Co) in 0.1 mol/L phosphate buffer adjusted to pH 7.4. TTC stained the noninfarcted myocardium a brick-red color, indicating the presence of a formazin precipitate that results from the reduction of TTC by dehydrogenase enzymes present in viable tissues. Infarct size was expressed as a percent of the area at risk.
Measurements of Regional Coronary Blood Flow
Regional myocardial blood flow was determined by the microsphere technique as previously reported.23,24 Nonradioactive microspheres (Sekisui Plastic Co, Ltd, Tokyo) are made of inert plastic labeled with different types of stable heavy elements as described in detail in previous studies. 23, 24 In the present study, microspheres labeled with bromine or zirconium were used. Mean diameter was 15 ,um, and specific gravity was 1.34 for bromine and 1.36 for zirconium. Microspheres were suspended in isotonic saline with 0.01% Tween 80 to prevent aggregation. The microspheres were ultrasonicated for 5 minutes followed by 5 minutes of vortexing immediately before injection. Approximately 1 mL of the microsphere suspension (2 to 4x 106 microspheres) was injected into the left atrium followed by several warm (37°C) saline flushes (5 mL). Microspheres were administered at 80 minutes after the onset of coronary occlusion. Just before microsphere administration, a reference blood flow sample was withdrawn from the femoral artery at a constant rate of 8 mL/min for 2 minutes.
The x-ray fluorescence activity of stable heavy elements was measured by a wavelength dispersive spectrometer (PW 1480, Phillips Co, Ltd). Specification of this x-ray fluorescence spectrometer has been described previously.23 '24 In brief, when the microspheres are irradiated by the primary x-ray beam, the electrons fall back to a lower orbit and emit measurable energy. This energy level of the x-ray fluorescence is characteristic for each element. Therefore, it is possible to quantify the x-ray fluorescence of several differently labeled microspheres in a mixture. Myocardial blood flow was calculated according to the formula time flow equals tissue counts times reference flow divided by reference counts and was expressed in milliliters per minute per gram of wet weight. We measured end endomyocardial blood flow of the inner half of the left ventricular wall.
Myocardial Metabolism
The coronary arterial and venous blood oxygen difference (AVo2D) was determined as the difference between coronary arterial and venous oxygen content. MVo2 (mL/100 g per minute) was calculated as CBF (mL/100 g per minute) times AVo2D (mL/dL).
Adenosine Measurement
The technique for measuring the plasma adenosine concentration (pmol/mL) has been reported previously.20'25-27 Briefly, 1 mL of blood was drawn into a syringe containing 0.5 mL of dipyridamole (0.02%) and 100 pL of 2'-deoxycoformycin (0.1 mg/mL) with EDTA (500 mmol/L) to block both the uptake of adenosine by red blood cells and degradation of adenosine. After centrifugation, the supernatant was collected and its adenosine content was measured by radioimmunoassay. The plasma adenosine (100 ,uL) was succinylated with 100 ,uL of dioxane containing succinic acid anhydride and triethylamine. After a 20-minute incubation, the mixture was diluted with 100 ,uL of adenosine 2',3'-0-disuccinyl-3-[Il5-iodotyrosine methyl ester (0.5 pmol/L) and 100 ,L of diluted antiadenosine serum. The mixture was kept in a cold water bath (4°C) for 18 hours, and the second antibody solution (goat anti-rabbit IgG antiserum, 500 ,L) was added. After incubation at 4°C for 1 hour, the unreacted material was removed by centrifugation at 3000 rpm at 4°C for 20 minutes. The radioactivity remaining in the tube was counted using a gamma counter. The amount of adenosine degraded during this blood sampling procedure has been reported to be negligible. [25] [26] [27] Myocardial S'-Nucleotidase Activity A biopsy specimen of subendocardial myocardium supplied by the LAD and LCx coronary arteries was obtained before sustained coronary occlusion with and without ischemic preconditioning in protocol 2. The myocardial tissue samples were frozen and stored under liquid nitrogen, and the ectosolic and cytosolic 5'-nucleotidase activity were measured at membrane and cytosolic fractions.
The myocardium was separated into its membrane and cytosolic fractions as follows: Myocardial tissue was homogenized using a Potter-Elvehjem homogenizer (30 strokes) for membrane fraction, part of the homogenate was centrifuged at 1000g for 10 minutes. The resulting pellet was washed three times and resuspended in the HEPES-KOH buffer. To prepare the cytosolic fraction, the remaining part of the homogenate was first centrifuged at 3000g for 10 minutes, and the supernatant was centrifuged at 200 000g for 1 hour. The membrane and cytosolic fractions were dialyzed at 4°C for 4 hours against 10 mmol/L HEPES-KOH (pH 7.4) containing 1 mmol/L MgCl2, 1 mmol/L mercaptoethanol, and 0.01% activated charcoal and were divided into aliquots that were frozen immediately and stored at -80°C. In the preliminary study, we examined the recovery of the 5'-nucleotidase activity in the membrane fraction in this procedure and observed that the recovery of ectosolic 5'-nucleotidase is 97±2% (n=5). This recovery is highly reproducible. 20 5'-Nucleotidase activity was assessed by the enzymatic assay technique20'28 and is reported as units of nmol/mg protein per minute. Protein concentration was measured by the method of Lowry et al,29 using bovine serum albumin as standard.
Statistical Analysis
Statistical analyses were performed using paired and unpaired t tests,30 and the significance level was adjusted accord- 
Results
CPP, CBF, and adenosine concentration during the period of hemodynamic stabilization with and without the ischemic preconditioning procedure were compared (Tables 1 through 4) . During 40 minutes of hemodynamic stabilization (Tables 2 and 4) , CPP, CBF, nor adenosine concentrations in the coronary arterial and venous blood changed significantly among the groups. During the ischemic preconditioning procedure with and without AOPCP administration (Tables 1 and 3) , although CPP was unchanged, CBF was increased during reperfusion after brief periods of ischemia. AOPCP attenuated the extent of the reactive coronary hyperemic flow during reperfusion after brief periods of ischemia in the ischemic preconditioning procedure ( Table 1 ). The adenosine concentration in coronary venous blood collected during reperfusion was significantly increased (P<.001), and it gradually augmented with repeated cycles of reperfusion after coronary occlusion in the ischemic preconditioning group (Table 3) . AOPCP treatment during the ischemic preconditioning procedure in the AOPCP treatment with IP group and the AOPCP pretreatment with IP group attenuated adenosine release during reperfusion after brief periods of ischemia compared with the IP group (Table 3) . In all of the groups in which we performed ischemic preconditioning (Tables 1 and 3 ), 5 minutes after the fourth cycle of coronary occlusion, CPP, CBF, and adenosine concentration in the coronary venous blood returned to the control levels (Tables 2 and 4). As observed in the previous study,20 Table 5 shows that ischemic precondi- tioning significantly increases both ectosolic and cytosolic 5'-nucleotidase activity of the myocardium compared with the control group. (Table 3 ). In the IP group, adenosine release was significantly higher after the onset of coronary reperfusion compared with the control group ( 38 .8±4.9%, NS), arguing the cause-and-effect relation between the increased ectosolic 5'-nucleotidase activity and the infarct size-limiting effect in ischemic preconditioning. In the AOPCP pretreatment with IP and the AOPCP during reperfusion with IP groups, infarct size was partially attenuated compared with the AOPCP treatment with IP group and the AOPCP treatment group. Infarct sizes of these two groups were smaller (P<.001) than the control and AOPCP groups and larger (P<.001) than that in the IP group. Fig 3 depicts the relation between infarct size normalized by risk area and collateral blood flow to inner half of the LAD- (3) administration of AOPCP during ischemic preconditioning procedures and during the reperfusion period partially blunts the infarct size-limiting effect. These results indicate that both increased 5'-nucleotidase activity and adenosine release during ischemic preconditioning procedures and during early reperfusion synergistically contribute to the infarct size-limiting effect of ischemic preconditioning.
Discussion Linkage Between the Infarct Size-Limiting Effect and Adenosine in Ischemic Preconditioning
Ischemic preconditioning has been the focus of studies by basic and clinical investigators in cardiology. Several laboratories have reported that ischemic preconditioning potently attenuates infarct size. [1] [2] [3] [12] [13] [14] [15] [16] [17] [18] [19] [20] However, the subcellular mechanisms must be elucidated to apply the results of ischemic preconditioning in the treatment of acute myocardial infarction because it is impractical to initiate brief periods of ischemia in clinical settings. Interestingly and timely, we have demonstrated that ischemic preconditioning increases both adenosine release and 5'-nucleotidase activity during ischemia and reperfusion.19,20 Furthermore, the present study revealed that inhibition of ectosolic 5'-nucleotidase activity and attenuation of enhanced release of adenosine blunts the infarct size-limiting effect of ischemic preconditioning. Since adenosine is known to limit infarct size2122 and to attenuate contractile dysfunction32-34 during ischemia and reperfusion, this augmentation of adenosine release during reperfusion after sustained ischemia can attenuate the infarct size in ischemic preconditioning.
Several lines of evidence support the idea that a transient exposure to adenosine modulates myocardial cellular function and attenuates infarct size.12-18 This observation is consistent with our previous19.20 and present results. We have reported that both ectosolic 5'-nucleotidase activity and adenosine release are increased during the ischemic preconditioning procedure as well as during reperfusion after sustained ischemia. Furthermore, in the present study, when adenosine release during the ischemic preconditioning procedure was attenuated by pretreatment with AOPCP, attenuation of infarct size was partially blunted, although AOPCP pretreatment did not attenuate the enhanced release of adenosine during reperfusion after sustained ischemia compared with the control group. We have though 5'-AMP decreases after 20 and 40 3-minute coronary occlusions. Third, the ability of membrane transport of adenosine also may affect the amount of adenosine release. Fourth, cytosolic 5'-nucleotidase also may be involved in adenosine release during reperfusion since cytosolic 5'-nucleotidase has a higher Km (Michaelis constant) for 5'-AMP than does ectosolic 5'-nucleotidase but may easily access 5'-AMP degraded from ATP and ADP in cytoplasm.44'49 However, ectosolic 5'-nucleotidase activity, which is thought to link with ischemic preconditioning, has lower Km and easily produces adenosine. We showed in the present study that ischemic preconditioning increases 5'-nucleotidase activity in the myocardium, and in turn, attenuation of ectosolic 5'-nucleotidase activity blunts adenosine release and the infarct size-limiting effect in ischemic preconditioning. Thus, we suggest the cause-and-effect relation between increases in adenosine production and activity of ectosolic 5'-nucleotidase. Interestingly, since ectosolic 5'-nucleotidase produces adenosine outside the cardiomyocytes and endothelial cells, this topical advantage to exert the action of adenosine on its A1-receptors may primarily contribute to attenuation of infarct size.
In the present study, we did not clarify the mechanisms of increased 5'-nucleotidase activity. We have recently observed that protein kinase C increases ectosolic and cytosolic 5'-nucleotidase activity in the in vivo measurements.4647 Since protein kinase C is activated by ischemia per se and by norepinephrine released during brief periods of ischemia, the ischemic preconditioning procedure may increase ectosolic and cytosolic 5'-nucleotidase activity through protein kinase C activation and therefore precondition the myocardium. If protein kinase C is responsible for increased 5'-nucleotidase activity and thereby the infarct size-limiting effects in ischemic preconditioning, a,-adrenoceptor stimulation may mimic ischemic preconditioning. Indeed, several groups of investigators, including those of our laboratory, preliminarily observed that a1-adrenoceptor activation is tightly involved in ischemic preconditioning. 18. 19.48 -5 Clinical Relevance
The present study revealed that adenosine release through ectosolic 5'-nucleotidase activity potently limits infarct size in ischemic preconditioning, which may lead to two clinical applications for the treatment of acute myocardial infarction. One strategy to limit infarct size is to find the method to increase 5'-nucleotidase activity. As we observed, protein kinase C activation by administration of a-adrenoceptor stimulants or phorbol esters may increase both 5'-nucleotidase activity and adenosine production and may merit attenuation of infarct size. Furthermore, exposures to cytokines51 are reported to increase 5'-nucleotidase activities. Oxygen-derived free radicals are also reported to attenuate the degradation of ectosolic 5'-nucleotidase activity.52 Therefore, administration of superoxide dismutase during ischemia and reperfusion may lessen the tendency for the decreased activity of ectosolic 5'-nucleotidase activity.
Another possibility aside from increased 5'-nucleotidase activity is to enhance adenosine release. Administration of a potentiator of adenosine production, eg, acadesine, dilazep, and dipyridamole,145354 may be effective for the attenuation of infarct size. These hypoth-eses are worth testing in clinical settings to find and develop a new strategy for the treatment of acute myocardial infarction, although further basic understanding of ischemic preconditioning is necessary.
